NOVEL ENCAPSULATION OF FLUORESCENT, PHOTO-SENSITIVE, OR OXYGEN-SENSITIVE ACTIVE INGREDIENT FOR TOPICAL APPLICATION
A topical composition for treatment of a skin condition comprising a fluorescent, photosensitive, or oxygen sensitive active ingredient encapsulated in a plurality of tubular microparticles for pharmaceutical use in humans is described. Some embodiments comprise a topical composition for treatment of acne that comprises an encapsulation of a tetracycline class drug, such as crystalline minocycline, in a plurality of microparticles, wherein the microparticles comprise a divalent cation, such as Mg 2+ or Zn 2+ . The tubular microparticles may comprise Mg 2 CO 3 . Benefits of various embodiments include the lack of visible fluorescence from a fluorescent active ingredient, reduced UV degradation of a photosensitive active ingredient, reduced UV degradation of an oxygen sensitive active ingredient, sun protection factor for the skin, and sustained delivery of a therapeutic dose.
1 . A topical composition for the treatment or prophylaxis of a dermatological pathology, comprising
an antibiotic active ingredient, and
a plurality of tubular microparticles comprising an enclosed volume,
wherein a portion of the antibiotic active ingredient is included within said enclosed volume of said tubular microparticles, and
wherein at least two tubular microparticles of the plurality of microparticles have a minimum cross-sectional dimension in the range of 1 to 50 micrometers.
2 . The topical composition of claim 1 , wherein
the antibiotic active ingredient is photosensitive, and
wherein a rate of degradation of a potency of the antibiotic active ingredient when exposed to an ultraviolet illumination is at least 10% lower than the degradation of the potency of the antibiotic active ingredient when exposed to the ultraviolet illumination for the topical composition prepared without the plurality of tubular microparticles.
3 . The topical composition of claim 1 , further comprising
at least two inactive ingredients,
wherein the amount of fluorescence from the topical composition when illuminated with UV illumination is at least 80% lower than the amount of fluorescence for a comparison mixture consisting of the at least two inactive ingredients and the fluorescent antibiotic active ingredient mixed in the same relative proportions as in the topical composition.
4 . The topical composition of claim 1 , wherein
the antibiotic active ingredient is fluorescent and photosensitive, and
the topical composition is neither fluorescent nor photosensitive.
5 . The topical composition of claim 1 , wherein
the antibiotic active ingredient is oxygen sensitive, and
the topical composition is not oxygen sensitive.
6 . The topical composition of claim 1 , wherein
a portion of the plurality of microparticles comprise microparticles with an internal volume in the range of 10 cubic micrometers to 1000 cubic micrometers.
7 . The topical composition of claim 1 , wherein
the ratio of mass of the antibiotic active ingredient to mass of the plurality of tubular microparticles is in the range of 1:1000 to 15:1.
8 . The topical composition of claim 1 , wherein
a portion of the plurality of tubular microparticles comprise a compound with a divalent cation.
9 . The topical composition of claim 8 , wherein
the divalent cation is chosen from the list consisting of a magnesium cation and a zinc cation.
10 . The topical composition of claim 9 , wherein
a portion of the plurality of tubular microparticles comprise magnesium carbonate.
11 . The topical composition of claim 10 ,
wherein the antibiotic active ingredient comprises a cycline-class drug, and
wherein the molar ratio of the cycline-class drug to magnesium carbonate in the composition is in the range of 0.001 to 0.75.
12 . The topical composition of claim 1 , wherein
a portion of the plurality of tubular microparticles react with acids on the skin to degrade one or more of the strength and the integrity of the portion of the plurality of tubular microparticles.
13 . The topical composition of claim 1 , wherein
the topical composition comprises an ingredient that is activated by light.
14 . The topical composition of claim 1 , wherein
the antibiotic active ingredient comprises an ingredient chosen from the list consisting of a cycline-class drug and a mycin-class drug.
15 . The topical composition of claim 1 , wherein
the antibiotic active ingredient is minocycline or doxycycline.
16 . The topical composition of claim 1 , further comprising
a material with a melting temperature in the range of 20 to 40 degrees Celsius.
17 . The topical composition of claim 1 , wherein
the topical composition releases active the antibiotic active ingredient in the application environment at a rate in the range of 10% per hour to 90% per hour.
18 . The topical composition of claim 1 , wherein
at least two tubular microparticles of the plurality of microparticles have a maximum cross-sectional dimension in the range of 10 to 500 micrometers, inclusive.
19 . The topical composition of claim 1 , wherein
the topical composition has a sun protection factor and the sun protection factor is within the range of 4 to 100, inclusive.
20 . A method for treatment or prophylaxis of a dermatological pathology comprising the steps of
applying the composition of claim 1 to a person's skin, and
repeating the applying step daily for a period of at least 6 weeks.